At a glance
A GHRH analogue with research in specific metabolic and endocrine settings.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Visceral-fat findings in HIV-associated lipodystrophy are a specific evidence context. They should not be generalized to all weight-management goals or research formulations.[3][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tesamorelin.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard FDA-Approved Protocol (3.0 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 15 units (0.15 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.
Additional schedule context & duration
Concise summary of the FDA-approved once-daily regimen.
- Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
- Schedule: Daily subcutaneous injections for 12–26 weeks (extendable to 52 weeks with medical supervision)[3].
- Dose: 2 mg (2000 mcg) daily after Week 1 titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate measurement.
- Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.
FDA-approved daily dosing approach with tolerability titration.
- Week 1: 1 mg (1000 mcg) once daily to assess tolerability.
- Weeks 2+: 2 mg (2000 mcg) once daily (standard FDA-approved dose)[7][7].
- Frequency: Once per day (subcutaneous), preferably in the evening.
- Cycle Length: 12–26 weeks; clinical trials support up to 52 weeks with monitoring[3].
- Timing: Evening administration recommended; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 7 days when reconstituted with bacteriostatic water[1].
Storage Instructions
Proper storage preserves peptide quality and efficacy.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1].
- Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days[1].
- Reconstituted (with sterile water): Use immediately; discard any unused portion[1].
- Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.
Injection Technique
Subcutaneous injection best practices from clinical guidelines[8].
- Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
- Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel)[6].
- Insert the needle at 90° (if adequate subcutaneous fat) or 45° (if lean)[8].
- Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing.
- Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy[6].
- Dispose of used syringes immediately in a puncture-proof sharps container[8].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol at the standard 2 mg dose (after Week 1 titration).
-
Peptide Vials (Tesamorelin, 20 mg each):
- 8 weeks ≈ 6 vials (105 mg total)
- 12 weeks ≈ 9 vials (161 mg total)
- 16 weeks ≈ 11 vials (217 mg total)
-
Insulin Syringes (U-100, 1 mL capacity):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
- 02
Source document
Tesamorelin (Subcutaneous route) – Drug Information — Mayo Clinic / IBM Merative (2025) (opens in a new tab)www.mayoclinic.org
Back to overview ↑ - 04
- 06
Public health resource
Tesamorelin Injection – MedlinePlus Drug Information — MedlinePlus (U.S. National Library of Medicine) (2025) (opens in a new tab)medlineplus.gov
Back to overview ↑ - 08
Public health resource
Administration of Parenteral Medications – Nursing Skills (Open RN Textbook) — Open RN, Chippewa Valley Technical College (2023) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.